eye diseases
The AI decision-support system, trained on multimodal ophthalmic data, will assist in diagnosis, treatment planning, and disease monitoring and management.
The company will use the funds for the global introduction of its robotic retinal imaging, AI and teleophthalmology platform.
This model, developed by the Chinese University of Hong Kong and Beijing Tongren Hospital, is now being deployed across China's Henan Province to diagnose common eye diseases.
Also, Syntekabio has launched its cloud service platform for AI drug discovery.